News
06-02-2017, 12:50 PM
A Yale Cancer Center clinical trial combining the immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as preoperative treatment for early stage triple negative breast cancer disclosed a 71% pathologic complete response to the combination treatment in the initial phase I trial.
More... (http://www.news-medical.net/news/20170602/Immunotherapy-combination-offers-new-hope-for-women-with-early-stage-triple-negative-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20170602/Immunotherapy-combination-offers-new-hope-for-women-with-early-stage-triple-negative-breast-cancer.aspx)